Zoetis Inc. ZTS

NYSE · Healthcare · Drug Manufacturers - Specialty & Generic

$79.11

Close on Fri, 20 Nov 2026 · market value $32.1B

What the price is betting on

Below its record

At $79, the price assumes revenue shrinks about 3.5% a year for five years, from $9.5B to about $8.2B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes−3.5%
Analysts, next two years0.2%
Last 3 years4%

Revenue growth a year. The price figure comes from a reverse DCF at a 7.9% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than ZTS? Check up to 5 of your stocks at once, free, no account.

0$5B$10B$15B$9.5B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$81

Base

$105

Bull

$121

Today $79

  • Bear $81. The dog and cat slowdown is structural, not a pause. Fewer vet visits, owners trading down, rising vet costs and more competition keep the largest line shrinking, and weaker livestock lines do not offset it. Cash flow declines for several years, a little faster than the market price already implies.
  • Base $105. Pet-care demand and pricing stay under pressure for a few years, with guided revenue below last year, but cattle and other species offset part of the dog and cat drop. Cash flow edges up slowly, and margins and returns stay close to today's very high levels.
  • Bull $121. The demand dip proves temporary. Newer products, the shift toward cats and growth in cattle, swine and fish offset weaker dog demand, so growth recovers part of the way toward the pace of two years ago while margins hold.

AI-written stories, valued by code from the same model.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$9.4B$9.3B, on the path
  3. FY2027$9.1B$9.3B, on the path
  4. FY2028$8.8B$9.6B, on the path
  5. FY2029$8.5B$10.1B, on the path
  6. FY2030$8.2B$10.5B, on the path

Each year's revenue at −3.5% growth from $9.5B in the 12 months to September 2026.

At a glance

Healthcare · Drug Manufacturers - Specialty & Generic · listed on NYSE

Revenue, FY2025
$9.5B
Growth, 3 years a year
4%
Cash margin
24%
Net debt
$7B
Shares, 3-year change
−5.6%
Dividend yield
2.8%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.